Article Sidebar

pdf
Date Published: 24/11/2023
Abstract Views: 94
Views pdf: 81
DOI: https://doi.org/10.51298/vmj.v532i1.7343
Issue
Vol. 532 No. 1 (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. D. D., & Vũ, H. T. (2023). THE EFFICACY OF IRINOTECAN MONOTHERAPY AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED GASTRIC CANCER. Vietnam Medical Journal, 532(1). https://doi.org/10.51298/vmj.v532i1.7343

THE EFFICACY OF IRINOTECAN MONOTHERAPY AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED GASTRIC CANCER

Thị Dương Dương Nguyễn1,, Hồng Thăng Vũ1,2
1 HMU
2 K Hospital

Main Article Content

Abstract

Objectives: To evaluate the efficacy of irinotecan monotherapy as second – line treatment in patients with advanced gastric cancer. Patiensand methods: Descriptive, retrospective, longitudinal case study of 43 patients with advanced gastric cancer refactory to or progressive after first – line chemotherapy, treatmented with irinotecan monotherapy as second-line treament from 01/2019 to 06/2023 at Vietnam’s National Cancer Hospital. Results: The mean age was 62,3 ± 11,7 (36-81); female/male ratio was 1/1,15. The overall response rate (ORR) was 18,6%, the DCR was 55,8%. The mean progression - free survival (PFS) was 4,0 ± 0,58 months, the median progression-free survival was 3,0 months. Conclusion: In patients with advanced gastric cancer, irinotecan  monotherapy is a resasonable second-line treatment option.

Article Details

Keywords

advanced gastric cancer, second-line treament, irionotecan monotherapy

References

Sung H., Ferlay J., Siegel R.L. và cộng sự. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209–249.
2. Thuss-Patience P.C., Kretzschmar A., Bichev D. và cộng sự. (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer, 47(15), 2306–2314.
3. Casaretto L., Sousa P.L.R., và Mari J.J. (2006). Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res, 39(4), 431–440.
4. Hironaka S., Ueda S., Yasui H. và cộng sự. (2013). Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol, 31(35), 4438–4444.
5. Eisenhauer E.A., Therasse P., Bogaerts J. và cộng sự. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247.
6. Cho Y.-H., Yoon S.Y., và Kim S.-N. (2017). Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis. Cancer Res Treat, 49(1), 255–262.
7. Lee K.-W., Maeng C.H., Kim T.-Y. và cộng sự. (2019). A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). Oncologist, 24(1), 18-e24.
8. Ochenduszko S., Puskulluoglu M., Konopka K. và cộng sự. (2017). Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. Ther Adv Med Oncol, 9(4), 223–233.